La Jolla Institute for Immunology, La Jolla, California, USA.
Department of Medicine, Division of Infectious Diseases and Global Public Health, La Jolla, California, USA.
Clin Infect Dis. 2022 Aug 15;75(Suppl 1):S24-S29. doi: 10.1093/cid/ciac310.
Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began 2 years ago, the scientific community has swiftly worked to understand the transmission, pathogenesis, and immune response of this virus to implement public health policies and ultimately project an end to the pandemic. In this perspective, we present our work identifying SARS-CoV-2 epitopes to quantify T-cell responses and review how T cells may help protect against severe disease. We examine our prior studies which demonstrate durable humoral and cell-mediated memory in natural infection and vaccination. We discuss how SARS-CoV-2-specific T cells from either natural infection or vaccination can recognize emerging variants of concern, suggesting that the currently approved vaccines may be sufficient. We also discuss how pre-existing cross-reactive T cells promote rapid development of immune memory to SARS-CoV-2. We finally posit how identifying SARS-CoV-2 epitopes can help us develop a pan-coronavirus vaccine to prepare for future pandemics.
自 2 年前严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)大流行开始以来,科学界迅速努力了解该病毒的传播、发病机制和免疫反应,以实施公共卫生政策,并最终预测大流行的结束。在这篇观点文章中,我们介绍了我们鉴定 SARS-CoV-2 表位以定量 T 细胞反应的工作,并回顾了 T 细胞如何帮助预防重症疾病。我们研究了先前的研究,这些研究表明自然感染和接种疫苗会产生持久的体液和细胞介导的记忆。我们讨论了来自自然感染或接种疫苗的 SARS-CoV-2 特异性 T 细胞如何识别新出现的关注变体,这表明目前批准的疫苗可能就足够了。我们还讨论了预先存在的交叉反应性 T 细胞如何促进对 SARS-CoV-2 的快速免疫记忆发展。最后,我们提出了如何通过鉴定 SARS-CoV-2 表位来帮助我们开发针对冠状病毒的通用疫苗,为未来的大流行做好准备。